Help

Search Results

8 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, ST 05

    A quantitative risk assessment approach to compare toxic emissions of electronic cigarettes with combustible cigarettes

    LIU C.(1); BERNAL A.J.(2); HUANG Yilang(3); LIU Chuan(4); GRAFF D.W.(1); JIAN Xingtao(3)
    (1) RiskWise Solution LLC, Princeton, NJ, U.S.A.; (2) ToxCreative LLC, Laguna Hills, CA, U.S.A.; (3) RELX Technology, RELX International, Shenzhen, China; (4) Pinevale Ltd, Southampton, U.K.
    Electronic cigarettes (e-cigarettes) heat a nicotine-containing e-liquid that could significantly reduce the number and levels of inhaled toxicants compared to combustible cigarette smoke. A framework for analytical evaluation of the e-cigarette...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2023, Cancun, ST 30

    Perception of harm and addictive potential of the RELX Infinity electronic nicotine delivery system (ENDS) and future product use intentions of adult smokers switching from combustible cigarettes over eight weeks

    GRAFF D.W.(1); FEARON I.M.(2)
    (1) Cheerain HK Limited, Hong Kong, China; (2) whatIF? Consulting Limited, Harwell, U.K.
    Evidence supports that switching from cigarettes to ENDS reduces toxicant exposure; however, misperceptions of the relative harm of ENDS may discourage their use for smoking reduction/cessation. We assessed perceptions of harm and addictiveness of...
  3. TSRC, Tob. Sci. Res. Conf., 2021, 74, abstr. 24

    In-vitro toxicity testing of RELX Infinity tobacco and menthol flavored ENDS products compared to reference 1R6F cigarette

    LIU C.(1); MINET E.F.(2); GRAFF D.W.(1)
    (1) RELX International, Shenzhen, Guangdong, China; (2) Broughton Nicotine Services, Earby, Lancashire, UK
    In the Electronic Nicotine Delivery System (ENDS) Premarket Tobacco Product Application guidance, the FDA recommends a weight of evidence approach to demonstrate that ENDS products are appropriate for the protection of public health, including...
  4. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 04

    Reduction of harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    D’RUIZ C.D.(1); O’CONNELL G.(2); GRAFF D.W.(3)
    (1) Scientific Affairs Consultant, Fontem Ventures, B.V., Greensboro, NC, U.S.A.; (2) Fontem Ventures, B.V., Scientific and Regulatory Affairs, Amsterdam, The Netherlands; (3) Celerion, Lincoln, NE, U.S.A.
    Changes in fifteen urine, blood, and exhaled breath biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs), representing major classes of compounds reported by the FDA to be significant contributors to smoking-associated...
  5. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 23

    Pharmacokinetics of nicotine following single controlled use of a new type of tobacco: heated tobacco product

    GILES L.(1); YUKI D.(2); SHERWOOD N.(3); GRAFF D.W.(4); NEWLAND K.(4)
    (1) JT International SA, Ballymena, Co. Antrim, U.K.; (2) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (3) Neil Sherwood Consulting, Commugny, Switzerland; (4) Celerion, Lincoln, NE, U.S.A.
    Nicotine is one of the most characteristic compounds contained in any type of tobacco product including cigarettes. Previous studies have reported that different types of tobacco products display differences in nicotine pharmacokinetics. NHTP is a...
  6. TSRC, Tob. Sci. Res. Conf., 2016, 70, abstr. 23

    Reductions in biomarkers of exposure (BoE) to harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    O’CONNELL G.(1); GRAFF D.W.(2); D’RUIZ C.(3)
    (1) Fontem Ventures B.V, Amsterdam, The Netherlands; (2) Celerion Inc, Lincoln, NE, USA; (3) Fontem Ventures B.V Greensboro, NC, USA
    Changes in fifteen urine, blood and exhaled breath BoEs of HPHCs representing classes of compounds reported by FDA to be significant contributors to smoking-associated disease risks were measured in 105 clinical-confined subjects following...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2013, Seville, ST 22

    The statistical benefit of performing GLP bioanalysis using assays that have reduced variability

    FARMEN R.H.; NEWLAND K.E.; GRAFF D.W.; COMBS M.L.
    Celerion, Lincoln, NE, U.S.A.; Celerion, Zürich, Switzerland
    Since the tobacco industry is moving into the area of regulated bioanalysis, we have noted that there is confusion surrounding the type of regulatory standards required for analytical methods to be used for testing tobacco constituents and biomarkers...